NewGenIvf Group Limited(NIVF)Earnings, Financials & Key Ratios
NIVF•NASDAQ•Insurance & Managed Care
0.0× P/E·Price updated Jun 24, 2026
AboutNewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company is headquartered in Bangkok, Thailand.Show more
- Revenue$5M-13.0%
- Combined Ratio326.95%+169.4%
- Net Income$10M+1981.8%
- Return on Equity80.63%+235.4%
- Medical Cost Ratio79.78%+20.2%
- Operating Margin-226.95%-962.9%
- Net Margin209.02%+2263.1%
- ROA54.43%+518.1%
- Equity / Assets79.41%+291.7%
NIVF Key Insights
NewGenIvf Group Limited (NIVF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Unprofitable underwriting: 326.9% combined ratio
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NIVF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NIVF Price & Volume
NewGenIvf Group Limited (NIVF) stock price & volume — 10-year historical chart
Loading chart...
NIVF Growth Metrics
NewGenIvf Group Limited (NIVF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-7.36%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years178.23%
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-35.47%
TTM-
Return on Capital
10 Years-66.49%
5 Years-66.49%
3 Years-40.47%
Last Year-68.73%
NIVF Peer Comparison
NewGenIvf Group Limited (NIVF) competitors in Healthcare Providers (Non-Insurers) — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 37.23B | 259.97 | -171.03 | 35.9% | -9.05% | -15.13% | 0.13 | |
 PGNY | 2.11B | 26.89 | 41.37 | 10.4% | 5.23% | 13.34% | 0.05 | |
 TMHC | 6.72B | 71.93 | 9.26 | -0.57% | 8.83% | 10.84% | 0.37 | |
 HIMS | 7.18B | 32.70 | 64.12 | 59% | -0.56% | -2.48% | 2.34 | |
 ILMN | 26.6B | 175.09 | 32.13 | -0.78% | 19.43% | 32.84% | 0.94 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 IART | 1.38B | 17.78 | -2.64 | 1.53% | -30.15% | -47.65% | 1.95 | |
 QDEL | 831.28M | 12.21 | -0.73 | -1.89% | -45.57% | -56.31% | 1.46 |
Compare NIVF vs Peers
NewGenIvf Group Limited (NIVF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NIVF Income Statement
NewGenIvf Group Limited (NIVF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Revenue | 4.12M | 5.94M | 5.14M | 5.43M | 4.73M | 2.79M |
Revenue Growth % | - | 44.34% | -13.59% | 5.78% | -13.01% | - |
Medical Costs & Claims | 3.09M | 4.41M | 3.45M | 3.61M | 3.77M | 2.06M |
Medical Cost Ratio % | 75.11% | 74.13% | 67.26% | 66.37% | 79.78% | 73.65% |
Gross Profit | 1.02M▲ 0% | 1.54M▲ 50.0% | 1.68M▲ 9.3% | 1.83M▲ 8.6% | 955.85K▼ 47.7% | 735.96K▲ 0% |
Gross Margin % | 24.89% | 25.87% | 32.74% | 33.63% | 20.22% | 26.35% |
Gross Profit Growth % | - | 50.05% | 9.35% | 8.63% | -47.68% | - |
Operating Expenses | 826.02K | 1.14M | 1.64M | 2.99M | 11.68M | 3.39M |
OpEx / Revenue % | 20.06% | 19.16% | 31.93% | 54.99% | 247.17% | 121.29% |
Depreciation & Amortization | 342.54K | 303.94K | 229.71K | 206.26K | 499.5K | 346.85K |
Combined Ratio % | 95.17% | 93.29% | 99.19% | 121.36% | 326.95% | 194.94% |
Operating Income | 198.76K▲ 0% | -504.91K▼ 354.0% | 42.24K▲ 108.4% | -1.16M▼ 2846.1% | -10.73M▼ 824.7% | -2.85M▲ 0% |
Operating Margin % | 4.83% | -8.49% | 0.82% | -21.35% | -226.95% | -101.98% |
Operating Income Growth % | - | -354.03% | 108.37% | -2846.08% | -824.69% | - |
EBITDA | 541.3K | -200.96K | 271.95K | -953.74K | -10.23M | -1.41M |
EBITDA Margin % | 13.14% | -3.38% | 5.29% | -17.55% | -216.38% | -50.37% |
Interest Expense | 88.29K | 77.76K | 46.18K | 778.66K | 616.42K | 446.36K |
Non-Operating Income | -45.72K | -23.04K | -112K | -978K | -21.07M | -2.37M |
Pretax Income | 156.18K▲ 0% | 500.65K▲ 220.6% | 108.42K▼ 78.3% | -961K▼ 986.4% | 9.73M▲ 1112.4% | -896.62K▲ 0% |
Pretax Margin % | 3.79% | 8.42% | 2.11% | -17.69% | 205.84% | -32.1% |
Income Tax | 294.72K | 208.14K | 0 | -487K | 0 | -487K |
Effective Tax Rate % | 188.7% | 41.57% | 0% | 50.68% | 0% | 54.32% |
Net Income | -533▲ 0% | 458.67K▲ 86153.8% | 130.19K▼ 71.6% | -525K▼ 503.2% | 9.88M▲ 1981.8% | -461.62K▲ 0% |
Net Margin % | -0.01% | 7.72% | 2.53% | -9.66% | 209.02% | -16.53% |
Net Income Growth % | - | 86153.85% | -71.61% | -503.25% | 1981.79% | - |
EPS (Diluted) | -0.00▲ 0% | 62.52▲ 1302508.3% | 12.44▼ 80.1% | -22.31▼ 279.4% | 16.80▲ 175.3% | -0.78▲ 0% |
EPS Growth % | - | - | -80.11% | -279.38% | 175.32% | - |
EPS (Basic) | -0.00 | 62.52 | 12.44 | -22.31 | 16.80 | - |
Diluted Shares Outstanding | 262.19K | 262.19K | 262.19K | 588.24K | 588.24K | 588.24K |
NIVF Balance Sheet
NewGenIvf Group Limited (NIVF) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Assets | 1.41M | 2.9M | 4.49M | 3.58M | 32.72M | 3.78M |
Asset Growth % | - | 105.62% | 54.46% | -20.26% | 814.62% | -109.38% |
Total Investment Assets | 0 | 0 | 0 | 204K | 0 | 2.2M |
Long-Term Investments | 0 | 0 | 0 | 204K | 0 | 70.9M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 820.39K | 2.4M | 2.46M | 3.17M | 7.38M | 3.17M |
Cash & Equivalents | 28.76K | 27.56K | 54.1K | 457.74K | 758.62K | 457.74K |
Receivables | 750.35K | 2.32M | 519.55K | 2.36M | 1.07M | 4.21M |
Other Current Assets | 0 | 0 | 373.68K | 73.92K | 116.25K | 1.07M |
Goodwill & Intangibles | 0 | 0 | 0 | 0 | 23.05M | 0 |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 23.05M | 0 |
PP&E (Net) | 592.38K | 506.34K | 446K | 371.67K | 2.29M | 371.67K |
Other Assets | 0 | 0 | 1.58M | 33.33K | 0 | 33.33K |
Total Liabilities | 2.33M | 2.8M | 1.24M | 5.06M | 6.74M | 5.06M |
Total Debt | 925.97K | 452.04K | 332.55K | 3.03M | 4.86M | 3.03M |
Net Debt | 897.2K | 424.49K | 278.45K | 2.57M | 4.11M | 2.57M |
Long-Term Debt | 0 | 0 | 0 | 2.33M | 4.1M | 2.33M |
Short-Term Debt | 512.82K | 0 | 0 | 582.45K | 256.06K | 690.97K |
Total Current Liabilities | 2.07M | 2.56M | 1.12M | 2.72M | 2.37M | 2.72M |
Accounts Payable | 46.93K | 104.65K | 172.63K | 1.3M | 779.28K | 1.3M |
Deferred Revenue | 812.16K | 1.36M | 7.94K | 63.49K | 111.98K | 63.49K |
Other Current Liabilities | 0 | 0 | 0 | 554.38K | 262.62K | 554.38K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Total Equity | -914.91K▲ 0% | 100.68K▲ 111.0% | 3.25M▲ 3123.5% | -1.48M▼ 145.7% | 25.99M▲ 1853.8% | -1.28M▲ 0% |
Equity Growth % | - | 111% | 3123.54% | -145.65% | 1853.78% | -234.59% |
Shareholders Equity | -775.94K | 563.11K | 3.74M | -1.05M | 26.63M | -844.61K |
Minority Interest | -138.97K | -462.43K | -490.05K | -433.14K | -644.83K | -433.14K |
Retained Earnings | -1.05M | -591.54K | -461.35K | -985.99K | 8.89M | -985.99K |
Common Stock | 5.6K | 6.02K | 0 | 0 | 0 | 0 |
Accumulated OCI | 10.85K | 9.57K | -7.29K | 18.88K | -143.07K | 18.88K |
Return on Equity (ROE) | - | 455.56% | 7.78% | -59.53% | 80.63% | -1.76% |
Return on Assets (ROA) | -0.04% | 21.25% | 3.52% | -13.02% | 54.43% | -1.56% |
Equity / Assets | -64.76% | 3.47% | 72.33% | -41.42% | 79.41% | -33.79% |
Debt / Equity | - | 4.49x | 0.10x | - | 0.19x | -2.37x |
Book Value per Share | -3.49 | 0.38 | 12.38 | -2.52 | 44.18 | -2.17 |
Tangible BV per Share | -3.49 | 0.38 | 12.38 | -2.52 | 5.00 | -2.17 |
NIVF Cash Flow Statement
NewGenIvf Group Limited (NIVF) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | 1.43M | -527.12K | -1.79M | -8.26M | -10.93M | -6.73M |
Operating CF Growth % | - | -136.78% | -239.74% | -361.46% | -32.21% | -4664.08% |
Operating CF / Revenue % | 34.8% | -8.87% | -34.87% | -152.11% | -231.17% | -241.12% |
Net Income | -138.53K | 500.65K | 130.19K | -474.1K | 9.73M | -461.62K |
Depreciation & Amortization | 342.54K | 303.94K | 229.71K | 206.26K | 499.5K | 179.9K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 208.14K | 0 | -486.71K | 0 | 0 |
Other Non-Cash Items | 497.6K | -2.25M | -60.51K | 247.54K | -19.55M | -2.28M |
Working Capital Changes | 731.39K | 710.35K | -2.09M | -7.76M | -1.6M | -4.17M |
Cash from Investing | -16.57K | -69.69M | -69.85K | -53.05K | -7.56M | 17.9M |
Capital Expenditures | -16.57K | -94.45K | -69.85K | -53.05K | -4.75M | 13.58K |
Acquisitions | 0 | 0 | 0 | 0 | -1.05M | 0 |
Purchase of Investments | 0 | -69.69M | -780K | 0 | -760K | -573.28K |
Sale/Maturity of Investments | 0 | 0 | 0 | 0 | 0 | 18.46M |
Other Investing | 0 | 94.45K | 780K | 0 | -1M | 4 |
Cash from Financing | -1.54M | 70.27M | 1.91M | 8.68M | 18.99M | -11.02M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Stock Issued | 0 | 71.87M | 192.31K | 0 | 12.62M | 442.02K |
Debt Issuance (Net) | 495.6K | 108.73K | 1000K | 1000K | 1000K | 1.69M |
Other Financing | -2.04M | -1.71M | 0 | 98.64K | 29.76K | -18.61M |
Net Change in Cash | -77.43K▲ 0% | 54.72K▲ 170.7% | -615▼ 101.1% | 403.64K▲ 65731.9% | 300.88K▼ 25.5% | 176.08K▲ 0% |
Exchange Rate Effect | 50.51K | 0 | -46.13K | 44.97K | -206.05K | 30.95K |
Cash at Beginning | 106.19K | 0 | 54.72K | 54.1K | 457.74K | 169.66K |
Cash at End | 28.76K | 54.72K | 54.1K | 457.74K | 758.62K | 457.74K |
Free Cash Flow | 1.42M▲ 0% | -621.58K▼ 143.9% | -1.86M▼ 199.4% | -8.32M▼ 347.0% | -16.68M▼ 100.5% | -6.74M▲ 0% |
FCF Growth % | - | -143.88% | -199.35% | -346.99% | -100.5% | - |
FCF Margin % | 34.4% | -10.46% | -36.23% | -153.09% | -352.82% | -241.22% |
FCF per Share | 5.4 | -2.37 | -7.1 | -14.14 | -28.35 | -11.45 |
NIVF Key Ratios
NewGenIvf Group Limited (NIVF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Combined Ratio | 93.29% | 99.19% | 121.36% | 326.95% | 194.94% |
Medical Cost Ratio | 74.13% | 67.26% | 66.37% | 79.78% | 73.65% |
Return on Equity (ROE) | 455.56% | 7.78% | -59.53% | 80.63% | -1.76% |
Return on Assets (ROA) | 21.25% | 3.52% | -13.02% | 54.43% | -1.56% |
Equity / Assets | 3.47% | 72.33% | -41.42% | 79.41% | -33.79% |
Book Value / Share | 0.38 | 12.38 | -2.52 | 44.18 | -2.17 |
Debt / Equity | 4.49x | 0.10x | - | 0.19x | -2.37x |
Revenue Growth | 44.34% | -13.59% | 5.78% | -13.01% | - |
Related:NIVF Dividend History·NIVF Revenue History·NIVF Price History·NIVF P/E History·NIVF Financial Ratios·NIVF Institutional Holders
NIVF Frequently Asked Questions
NewGenIvf Group Limited (NIVF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NewGenIvf Group Limited (NIVF) saw revenue decline by 13.0% over the past year.
NewGenIvf Group Limited (NIVF) reported a net loss of $0.5M for fiscal year 2025.
Dividend & Returns
NewGenIvf Group Limited (NIVF) has a return on equity (ROE) of 80.6%. This is excellent, indicating efficient use of shareholder capital.
Industry Metrics
NewGenIvf Group Limited (NIVF) has a combined ratio of 326.9%. A ratio above 100% means claims and expenses exceed premiums.